Nonalcoholic fatty liver disease (NAFLD) is a dynamic chronic liver disease that develops in
close association with metabolic irregularities. Between 2016 and 2019, the global …

Non-alcoholic fatty liver disease (NAFLD) is now recognised as the most common liver
disease worldwide. It encompasses a broad spectrum of conditions, from simple steatosis …

Nonalcoholic fatty liver (NAFL) and its sequelae are growing health problems. We performed
a genome-wide association study of NAFL, cirrhosis and hepatocellular carcinoma, and …

Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global adult population and is
the most common chronic liver disease worldwide. Nonalcoholic steatohepatitis (NASH) is …

Lifestyle intervention can be effective when treating non-alcoholic fatty liver diseases
(NAFLD) patients. Weight loss decreases cardiovascular and diabetes risk and can also …

Non-alcoholic fatty liver disease (NAFLD) is to date the most common chronic liver disease
in clinical practice and, consequently, a major health problem worldwide. It affects …

Abstract Aims/hypothesis The EFFECT-II study aimed to investigate the effects of
dapagliflozin and omega-3 (n-3) carboxylic acids (OM-3CA), individually or combined, on …

Nonalcoholic fatty liver disease (NAFLD) refers to a group of conditions characterized by
hepatic steatosis in the absence of significant alcohol consumption. NAFLD is seen …

Background Non‐alcoholic steatohepatitis (NASH) is a severe form of non‐alcoholic fatty
liver disease (NAFLD) characterised by liver fat accumulation, inflammation and progressive …

OBJECTIVES: Some studies suggest that non-obese patients with nonalcoholic fatty liver
disease (NAFLD) may have more severe disease. We aim to study the epidemiology and …